Heterogeneity in disease severity in a family with a novel G68V GCK activating mutation causing persistent hyperinsulinaemic hypoglycaemia of infancy

Background/aim  Glucokinase (GCK)‐activating mutations cause persistent hyperinsulinaemic hypoglycaemia of infancy (PHHI). GCK‐PHHI patients have regulated insulin secretion and can usually be treated with diazoxide. The six reported cases suggest that the severity of the mutation predicts the clinical phenotype. The aim of this study was to relate genotype to phenotype [clinical phenotype, glucose‐stimulated insulin release (GSIR) and GCK functional analysis] in a large pedigree with eight affected individuals.

[1]  M. Magnuson,et al.  Glucokinase Thermolability and Hepatic Regulatory Protein Binding Are Essential Factors for Predicting the Blood Glucose Phenotype of Missense Mutations* , 2007, Journal of Biological Chemistry.

[2]  A. Hattersley,et al.  Macrosomia and Hyperinsulinaemic Hypoglycaemia in Patients with Heterozygous Mutations in the HNF4A Gene , 2007, PLoS medicine.

[3]  J. Gulcher,et al.  Refining the impact of TCF7L2 gene variants on type 2 diabetes and adaptive evolution , 2007, Nature Genetics.

[4]  D. Melzer,et al.  A common haplotype of the glucokinase gene alters fasting glucose and birth weight: association in six studies and population-genetics analyses. , 2006, American journal of human genetics.

[5]  F. Ashcroft,et al.  A heterozygous activating mutation in the sulphonylurea receptor SUR1 (ABCC8) causes neonatal diabetes. , 2006, Human molecular genetics.

[6]  A. Hattersley,et al.  KCNJ11 activating mutations are associated with developmental delay, epilepsy and neonatal diabetes syndrome and other neurological features , 2006, European Journal of Human Genetics.

[7]  H. Stefánsson,et al.  Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes , 2006, Nature Genetics.

[8]  Richard W Jones,et al.  Genetic regulation of birth weight and fasting glucose by a common polymorphism in the islet cell promoter of the glucokinase gene. , 2005, Diabetes.

[9]  A. Gloyn,et al.  Glucokinase and the Regulation of Blood Sugar , 2004 .

[10]  H. Huopio,et al.  Severe persistent hyperinsulinemic hypoglycemia due to a de novo glucokinase mutation. , 2004, Diabetes.

[11]  Teruyuki Nishimura,et al.  Structural basis for allosteric regulation of the monomeric allosteric enzyme human glucokinase. , 2004, Structure.

[12]  M. Coghlan,et al.  Stimulation of hepatocyte glucose metabolism by novel small molecule glucokinase activators. , 2004, Diabetes.

[13]  R. Dullaart,et al.  Family with autosomal dominant hyperinsulinism associated with A456V mutation in the glucokinase gene , 2004, Journal of internal medicine.

[14]  A. Hattersley,et al.  Insights into the biochemical and genetic basis of glucokinase activation from naturally occurring hypoglycemia mutations. , 2003, Diabetes.

[15]  J. Grippo,et al.  Allosteric Activators of Glucokinase: Potential Role in Diabetes Therapy , 2003, Science.

[16]  M. McCarthy,et al.  Large-scale association studies of variants in genes encoding the pancreatic beta-cell KATP channel subunits Kir6.2 (KCNJ11) and SUR1 (ABCC8) confirm that the KCNJ11 E23K variant is associated with type 2 diabetes. , 2003, Diabetes.

[17]  H. Huopio,et al.  A new subtype of autosomal dominant diabetes attributable to a mutation in the gene for sulfonylurea receptor 1 , 2003, The Lancet.

[18]  T. Frayling,et al.  Intrauterine hyperglycemia is associated with an earlier diagnosis of diabetes in HNF-1alpha gene mutation carriers. , 2002, Diabetes care.

[19]  A. Baudry,et al.  Improved metabolic disorders of insulin receptor-deficient mice by transgenic overexpression of glucokinase in the liver , 2002, Diabetologia.

[20]  Klaus Brusgaard,et al.  The second activating glucokinase mutation (A456V): implications for glucose homeostasis and diabetes therapy. , 2002, Diabetes.

[21]  M. Kaleko,et al.  Phenotypic correction of diabetic mice by adenovirus-mediated glucokinase expression. , 2001, Diabetes.

[22]  F M Matschinsky,et al.  Familial hyperinsulinism caused by an activating glucokinase mutation. , 1998, The New England journal of medicine.

[23]  F. Bosch,et al.  Correction of diabetic alterations by glucokinase. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[24]  S. Jasko,et al.  Therapy , 1881, The American journal of dental science.